
BLCO — Bausch + Lomb Corp
NYSE · Healthcare · Medical Instruments & Supplies
$18.42
+$0.54 (+3.02%)
Bausch + Lomb Corp (BLCO) is a medical instruments & supplies company listed on NYSE. It is led by Brenton L. Saunders J.D., based in 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4, with about 13,000 employees. Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Latest reported BLCO revenue for 2025-09-30 was $1.28B. Net income was -$25.0M. Revenue was up 0.2% from 2025-06-30 to 2025-09-30. BLCO currently screens at market cap $5.38B.
Use this BLCO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BLCO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BLCO SEC filings page. Lician reads the product cache first so this HTML stays unique to Bausch + Lomb Corp even when a live quote feed is slow.
About Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
BLCO Key Statistics
Market Cap
$5.38B
Volume
449,704
Previous Close
$17.32
Day Range
$17.00 – $17.44
P/B Ratio
0.84
EPS
-$0.90
Revenue
$4.79B
Net Income
-$305.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+15.6%
Profit Margin
-6.4%
Employees
13,000
BLCO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $4.79B | $4.15B | $3.77B | $3.77B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$305.00M | -$248.00M | $15.00M | $193.00M |
| EPS (Diluted) | -$0.90 | -$0.74 | $0.02 | $0.52 |
Total Assets
$13.47B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$305.00M
Operating Cash Flow
$232.00M
Free Cash Flow
$0.00
Bausch + Lomb Corp Company Information
- CEO & Chairman
- Brenton L. Saunders J.D.
- Headquarters
- 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
- Website
- www.bausch.com
- Phone
- 905 695 7700
- IPO / Founded
- 2022-05-06
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies